PACKAGE LEAFLET: INFORMATION FOR THE USER. Actilyse Cathflo 2 mg, poeder voor oplossing voor injectie en infusie. Alteplase

Similar documents
Annex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Package leaflet: Information for the patient. Trasylol 10,000 KIU/ml solution for injection or infusion. Aprotinin

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

ANNEX III LABELLING AND PACKAGE LEAFLET

Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil

PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

Cofact can be used for: The treatment of haemorrhages or the prevention of peri-operative haemorrhages as the result of

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

Package leaflet: Information for the user. Novastan 100 mg/ml concentrate for solution for infusion. argatroban monohydrate

Package leaflet: Information for the user. ReoPro 2 mg/ml solution for injection or infusion. abciximab

METALYSE Tenecteplase

Package leaflet: Information for the patient. Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine

Package leaflet: Information for the user

Package leaflet: Information for the patient. Hexvix 85 mg, powder and solvent for intravesical solution Hexaminolevulinate

PACKAGE LEAFLET: INFORMATION FOR THE USER. Calcium Folinate 10 mg/ml Injection

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dopamine 40 mg/ml Sterile Concentrate

Package leaflet: Information for the patient. Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab

Package leaflet: Information for the user. HEPATECT CP 50 IU/ml solution for infusion. Human hepatitis B immunoglobulin for intravenous administration

Piperacillin Tazobactam 4g/0.5g powder for solution for injection or infusion Piperacillin and tazobactam

Package leaflet: Information for the user. GlucaGen HypoKit 1 mg Powder and solvent for solution for injection Glucagon

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml solution for injection/infusion Cisatracurium 5 mg/ml solution for injection/infusion

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cisatracurium 2 mg/ml Solution for Injection/Infusion Cisatracurium 5 mg/ml Solution for Injection/Infusion

Package Leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the patient. Paracetamol 10 mg/ml solution for infusion. Paracetamol

COMPANY CORE PACKAGE INSERT CCPI (PI/CORE/ENGLISH)

Package leaflet: Information for the user. Paralink 10 mg/ml Solution for Infusion Paracetamol

Package leaflet: Information for the user. /.../ 50 mg powder and solvent for solution for injection/infusion. melphalan

Package leaflet: Information for the patient. Heparin Sodium BP 1000 IU/L in 0.9% w/v Sodium Chloride IV Infusion. Active substance: Heparin Sodium

Package leaflet: Information for the user

Package leaflet: Information for the user

LEUCOVORIN-TEVA 10 mg/ml CONCENTRATE FOR SOLUTION FOR INFUSION folinic acid as the calcium salt PACKAGE LEAFLET: INFORMATION FOR THE USER

2. What you need to know before you are given Konakion MM. Package Leaflet: Information for the patient

Package leaflet: Information for the patient. Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab

Package leaflet: Information for the user. Aminoven 5% Solution for infusion Aminoven 10% Solution for infusion Aminoven 15% Solution for infusion

Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid

Package leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER. Variquel 1 mg powder and solvent for solution for injection Terlipressin acetate

Package leaflet: Information for the user

CSL Behring. Beriplex P/N 250, 500 and 1000 IU Powder and solvent for solution for injection Human prothrombin complex

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone

Package leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER. Fibrovein 3%, 1%, 0.5% and 0.2% Solution for Injection Sodium tetradecyl sulphate

Package leaflet: Information for the user innohep 20,000 IU/ml tinzaparin sodium

PACKAGE LEAFLET: INFORMATION FOR THE USER. Human Albumin Biotest 20%, solution for infusion Human albumin

Package leaflet: Information for the user. Tobramycin 40 mg/ml Solution for Injection tobramycin

PACKAGE LEAFLET: INFORMATION FOR THE USER. CO-AMOXICLAV TEVA 1000 mg/200 mg POWDER FOR SOLUTION FOR INJECTION/INFUSION INJECTION/INFUSION

Package leaflet: Information for the patient. SYLVANT 400 mg powder for concentrate for solution for infusion. siltuximab

PACKAGE LEAFLET: INFORMATION FOR THE USER. Glucose Intravenous Infusion BP 10% w/v solution for infusion Glucose (as glucose monohydrate)

PACKAGE LEAFLET: INFORMATION FOR THE USER. / / 200 mg powder for solution for infusion / / 1 g powder for solution for infusion.

Package leaflet: Information for the user

PACKAGE LEAFLET: INFORMATION FOR THE USER. Zoledronic Acid IBIGEN 4 mg powder and solvent for solution for infusion Zoledronic acid

Package leaflet: Information for the user. multibic potassium-free solution for haemodialysis/haemofiltration

Package leaflet: Information for the patient. Selenium 10 micrograms/ml concentrate for solution for infusion. Sodium selenite

Package leaflet: Information for the user

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime

Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

Package Leaflet: Information for the User

Powder for reconstitution for use in central venous access devices

Artesunate 60 mg for injection WHOPAR part 3 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET

CONSUMER MEDICINE INFORMATION LEAFLET

1. What RoActemra is and what it is used for

Package leaflet: Information for the user. Cyanokit 5 g powder for solution for infusion hydroxocobalamin

PATIENT INFORMATION LEAFLET

Package leaflet: Information for the patient. Konakion MM Ampoules 10mg/ml solution for injection and oral solution Phytomenadione (vitamin K 1 )

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

Artesunate 60 mg for injection WHOPAR part 3 November 2015 (Guilin Pharmaceutical Co., Ltd.), MA051 PATIENT INFORMATION LEAFLET

1. What Naropin is and what it is used for

Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion Sodium chloride

Package leaflet: Information for the user. Piperacillin/Tazobactam Actavis 4 g / 0.5 g powder for solution for infusion. piperacillin / tazobactam

PACKAGE LEAFLET: INFORMATION FOR THE USER. octaplaslg mg/ml solution for infusion Human plasma proteins

Package leaflet: Information for the patient. Ruconest 2100 U powder and solvent for solution for injection Conestat alfa

Package leaflet: Information for the user

Package leaflet: Information for the user. Cyramza 10 mg/ml concentrate for solution for infusion ramucirumab

Package leaflet: Information for the patient. Leucovorine Sandoz 10 mg/ml, oplossing voor injectie folinic acid

Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride

Package leaflet: Information for the patient. ERWINASE 10,000 Units, Powder for solution for injection

Package leaflet: Information for the user. Bridion 100 mg/ml solution for injection sugammadex

Package leaflet: Information for the patient. Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid

Package leaflet: Information for the user. RIXUBIS 500 IU powder and solvent for solution for injection

Package leaflet: information for the user. Prismasol 2 mmol/l Potassium Solution for haemodialysis/haemofiltration

PACKAGE LEAFLET: INFORMATION FOR THE USER Etoposide Accord 20 mg/ml Concentrate for Solution for Infusion Etoposide

PACKAGE LEAFLET: INFORMATION FOR THE USER. Gemzar 200 mg powder for solution for infusion Gemzar 1000 mg powder for solution for infusion Gemcitabine

Package leaflet: Information for the patient

PACKAGE LEAFLET: INFORMATION FOR THE USER. Vancomycin Mylan 1000 mg, powder for concentrate for solution for infusion. Vancomycin

Package leaflet: Information for the patient. Gemcitabine 10 mg/ml, solution for infusion. gemcitabine

PACKAGE LEAFLET. Package leaflet: Information for the user. Vancomycin Hospira 1000 mg Powder for concentrate for solution for infusion.

PACKAGE LEAFLET: INFORMATION FOR THE USER. ETOPOSIDE-TEVA 20 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION etoposide

Package leaflet: Information for the patient. DOPAVIEW 222 MBq/mL solution for injection. Fluorodopa (18F)

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. (em-plis-city)

Package leaflet: Information for the user. Pemetrexed PharmaSwiss 500 mg powder for concentrate for solution for infusion.

Package leaflet: Information for the patient. Daptomycin 350 mg powder for solution for injection/infusion daptomycin

Before you use NovoThirteen. When NovoThirteen should not be used

The medicines you are using mixed with Water for injections may interact with each other.

Package leaflet: Information for the user. Tygacil 50 mg powder for solution for infusion Tigecycline

Transcription:

PACKAGE LEAFLET 1

PACKAGE LEAFLET: INFORMATION FOR THE USER Actilyse Cathflo 2 mg, poeder voor oplossing voor injectie en infusie Alteplase Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Actilyse Cathflo is and what it is used for 2. What you need to know before you receive Actilyse Cathflo 3. How is Actilyse Cathflo administered 4. Possible side effects 5. How to store Actilyse Cathflo 6. Contents of the pack and other information 1. What Actilyse Cathflo is and what it is used for The active substance in Actilyse Cathflo is alteplase. It belongs to a group of medicines called thrombolytic agents. These medicines act by dissolving blood clots. Actilyse Cathflo is used to clear catheters which are blocked by blood clots. 2. What you need to know before you get Actilyse Cathflo You should not receive Actilyse Cathflo if you are allergic (hypersensitive) to the active substance alteplase, to gentamicin (a trace residue from the manufacturing process), to natural rubber (also called latex which is part of the packaging material) or to any of the other ingredients of this medicine (listed in section 6). Your doctor will take special care with Actilyse Cathflo if you have had any allergic reaction other than a sudden life-threatening allergic reaction (severe hypersensitivity ) to the active substance alteplase, to gentamicin (a trace residue from the manufacturing process), to natural rubber (also called latex which is part of the packaging material) or to any of the other ingredients of this medicine (listed in section 6). if you have a bleeding in any part of the body if in the past 48 hours you have had a condition that increases your risk of bleeding, including: - surgery - biopsy (a procedure for obtaining a tissue specimen) - puncture - delivery of a baby if you have a bleeding disorder or tendency to bleed if you have severe liver or kidney disease if a blood vessel located close to the catheter is blocked by blood clots (venous thrombosis) if there is or may be an infection located in the catheter 2

Other medicines and Actilyse Cathflo Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. It is particularly important that you tell your doctor if you are taking or have recently taken: any medicines which are used to thin the blood, including: - acetylsalicylic acid - warfarin - coumarin - heparin certain medicines used to treat high blood pressure (ACE inhibitors). Pregnancy and breast-feeding Ask your doctor for advice before taking any medicine. Your doctor will only give you Actilyse Cathflo if the possible benefit outweighs the possible risk to your baby. Actilyse Cathflo may contain gentamicin as trace residue from the manufacturing process; the packaging contains natural rubber (latex). 3. How is Actilyse Cathflo administered Actilyse Cathflo will be prepared and administered to you by your doctor or by a healthcare professional. It is not for self-administration. The dose you are given depends on your body weight. The maximum dose of Actilyse Cathflo is 2 mg but will be lower if you weigh less than 30 kg. Actilyse Cathflo is filled in the blocked catheter. After 30 min your doctor will check if the catheter has already been cleared. If this is the case, treatment with Actilyse Cathflo will be stopped. If this is not yet the case, the product will remain in the catheter for another 90 min. After treatment, Actilyse Cathflo is removed from the catheter. The catheter is rinsed with sterile saline solution. If the catheter is still blocked after your first treatment with Actilyse Cathflo, the whole procedure may be repeated once. Actilyse Cathflo should not be mixed with other medicines. If you have any further questions on the use of this medicine, ask your doctor or nurse. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects described below have been experienced by people given Actilyse Cathflo: Uncommon (occurs in less than 1 in 100 patients receiving the medicine) release of an infection from the catheter to the blood vessels leading to blood poisoning (sepsis) damage to the catheter such as: - blockage - leakage - burst Rare (occurs in less than 1 in 1,000 patients receiving the medicine) fever 3

In principle, all undesirable effects as found for the application of Actilyse (10, 20, 50 mg of alteplase) for heart attacks, pulmonary embolism or stroke may also occur during treatment of catheters blocked by blood clots. This is however only possible in cases where Actilyse Cathflo (2 mg of alteplase) reaches the blood circulation. The following side effects may occur: (e.g. bleeding (haemorrhage), sudden blocking of a blood vessel (embolism), allergic (hypersensitivity/anaphylactoid) reactions, blood pressure decreased, nausea, vomiting, body temperature increased. However none of these side effects has ever been observed with Actilyse Cathflo so far. Due to the small amount of medicine used, these side effects are very unlikely to occur with Actilyse Cathflo (2 mg) apart from allergic reactions for which a small amount may be sufficient. When using the product Actilyse (10, 20, 50 mg of alteplase), allergic reactions have been observed rarely. Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine. 5. How to store Actilyse Cathflo Normally you will not be asked to store Actilyse Cathflo as it will be given to you by your doctor. Keep this medicine out of the sight and reach of children. Store in a refrigerator (2 8 C). Store in the original package in order to protect from light. Do not use this medicine after expiry date which is stated on the vial label and the carton. The expiry date refers to the last day of that month. Reconstituted solution The reconstituted solution has been demonstrated to be stable for 24 hours at 2 C 8 C and for 8 hours at 25 C. From a microbiological point of view, the product should be used immediately after reconstitution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 8 C. 6. Contents of the pack and other information What Actilyse Cathflo contains The active substance is alteplase. Each vial contains 2 mg (corresponding to 1,160,000 IU) alteplase. The other ingredients are arginine, phosphoric acid (for ph-adjustment) and polysorbate 80. The rubber stopper of the packaging material contains natural rubber (latex) What Actilyse Cathflo looks like and contents of the pack Actilyse Cathflo is a powder for solution for injection and infusion. Each pack contains five vials, each with 2 mg alteplase. Marketing Authorisation Holder Boehringer Ingelheim bv Comeniusstraat 6 1817 MS ALKMAAR Tel: 0800-2255889 4

Manufacturer Boehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Strasse 65 D-88397 Biberach/Riss Germany This leaflet was last revised in oktober 2018. ----------------------------------------------------------------------------------------------------------------------------- The following information is intended for medical or healthcare professionals only: Traceability In order to improve traceability of biological medicinal products, the trade name and the batch number of the administered product should be clearly recorded in the patient file. Instructions for reconstitution The 2 mg presentation of alteplase is not indicated for use in myocardial infarction, acute pulmonary embolism or acute ischaemic stroke (due to risk of massive underdosing). Only 10, 20 or 50 mg presentations are indicated for use in those indications. The 2 mg vial (with a total amount of 2.2 mg alteplase including 0.2 mg overage which will remain in the transfer syringe so that the amount practically administered is 2 mg alteplase) should always be reconstituted to a final concentration of 1 mg alteplase per ml. To this end, 2.2 ml sterile water for injection should be transferred to the vial containing the Actilyse Cathflo powder by use of a syringe with a suitable measuring precision under aseptic conditions. The reconstituted solution should then be instilled into the dysfunctional central venous access device. It may be diluted further with sterile sodium chloride 9 mg/ml (0.9 %) solution for injection up to a minimal concentration of 0.2 mg/ml since the occurrence of turbidity of the reconstituted solution cannot be excluded. A further dilution of the reconstituted solution with sterilised water for injections or in general, the use of carbohydrate infusion solutions, e.g. dextrose is not recommended due to increasing formation of turbidity of the reconstituted solution. Actilyse Cathflo should not be mixed with other medicinal products in the same catheter (not even with heparin). For incompatibilities see section 6.2 of the SmPC. When reconstituting the product from the respective amount of powder and solvent, the mixture should only be swirled gently until complete dissolution. Any vigorous agitation should be avoided to prevent foam formation. The reconstituted preparation is a clear and colourless to pale yellow solution. Prior to administration it should be inspected visually for particles and colour. For storage conditions, please see section 5 of this leaflet. The reconstituted solution is for single use only. Any unused solution should be discarded. Instructions for administration in occluded central venous access devices including those used for haemodialysis 5

1. Reconstitute the content of an injection vial to a final concentration of 1 mg alteplase per ml. For catheters with a lumen volume greater than 2 ml, the reconstituted solution can be further diluted with sterile sodium chloride 9 mg/ml (0.9 %) solution for injection to the desired volume. I.e. for a catheter with internal volume of 2.5 ml the total dose of Actilyse Cathflo would be 2.0 mg in a volume of 2.5 ml. 2. Instil the appropriate dose of Actilyse Cathflo into the dysfunctional central venous access device. 3. After 30 minutes of dwell time, assess catheter function by attempting to aspirate blood. If the catheter is functional, go to Step 6. If the catheter is not functional, go to Step 4. 4. After 120 minutes of dwell time, assess catheter function by attempting to aspirate blood and catheter contents. If the catheter is functional, go to Step 6. If the catheter is not functional, go to Step 5. 5. If catheter function is not restored after the first dose, a second dose of equal amount may be instilled. Repeat the procedure beginning with Step 1. If after a second dose of alteplase the device remains dysfunctional consider device replacement. 6. If catheter function has been restored, aspirate 4 5 ml of blood in patients weighing 10 kg or more, or 3 ml in patients with a body weight below 10 kg to remove Actilyse Cathflo and residual clot, and gently irrigate the catheter with sterile sodium chloride 9 mg/ml (0.9 %) solution for injection. 6